SeekingAlpha · Aug 19, 2026
Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction
Journey Medical Emrosi growth drives a 23% Q2 revenue jump and positive EBITDA. Click for more on DERM stock.
DE
NASDAQ · DERM
Journey Medical Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
$7.75
Up+$0.26 (+3.47%)
Updated Aug 22, 2026, 11:05 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 178.63M
- P/E ratio
- -20.66
- Dividend yield
- 0.00%
- 52-week range
- $4.31 – $9.56
- Volume
- 264.03K
- Avg. volume
- 167.08K
Price performance
DERM price history
1M range · 21 trading sessions · Daily adjusted prices
DERM closed at $7.75 after 21 trading sessions, up 25.20% for the selected period.
- Last close
- $7.75
- Period change
- +25.20%
- Period low
- $6.15
- Period high
- $7.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $7.56 | $8.095 | $7.56 | $7.75 | 264.03K |
| Aug 20, 2026 | $6.80 | $7.75 | $6.80 | $7.49 | 338.55K |
| Aug 19, 2026 | $6.79 | $6.94 | $6.64 | $6.81 | 150K |
| Aug 18, 2026 | $6.44 | $6.74 | $6.44 | $6.66 | 207.79K |
| Aug 17, 2026 | $6.73 | $6.81 | $6.44 | $6.46 | 290.59K |
| Aug 14, 2026 | $6.67 | $6.80 | $6.505 | $6.72 | 281.64K |
| Aug 13, 2026 | $7.35 | $7.64 | $6.55 | $6.65 | 705.24K |
| Aug 12, 2026 | $6.43 | $6.49 | $6.22 | $6.43 | 262.49K |
| Aug 11, 2026 | $6.50 | $6.655 | $6.30 | $6.32 | 215.18K |
| Aug 10, 2026 | $6.43 | $6.62 | $6.265 | $6.44 | 185.54K |
| Aug 7, 2026 | $6.62 | $6.7699 | $6.40 | $6.43 | 390.88K |
| Aug 6, 2026 | $6.40 | $6.56 | $6.3772 | $6.53 | 253.33K |
| Aug 5, 2026 | $6.41 | $6.505 | $6.39 | $6.40 | 148.62K |
| Aug 4, 2026 | $6.44 | $6.7327 | $6.40 | $6.40 | 163.53K |
| Aug 3, 2026 | $6.37 | $6.61 | $6.27 | $6.47 | 249.51K |
| Jul 31, 2026 | $6.43 | $6.54 | $6.20 | $6.37 | 47.05K |
| Jul 30, 2026 | $6.22 | $6.56 | $6.20 | $6.45 | 82.54K |
| Jul 29, 2026 | $6.28 | $6.55 | $6.14 | $6.15 | 183.47K |
| Jul 28, 2026 | $6.34 | $6.39 | $6.14 | $6.31 | 131.71K |
| Jul 27, 2026 | $6.37 | $6.40 | $6.10 | $6.37 | 133.76K |
| Jul 24, 2026 | $6.58 | $6.665 | $6.00 | $6.19 | 313.64K |
Latest DERM news
The latest Smart Investors Daily articles mentioning DERM.
Stock researchCompany · Overview
DERM research
Overview
Company profile and research snapshot.
Company profile
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | B. Riley Securities | Buy | — |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 25, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2025 | Lake Street | Buy | — |
| Jul 30, 2025 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.
SeekingAlpha · Aug 12, 2026
Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsJaclyn Jaffe - Senior Director of Corporate...
Benzinga · Aug 12, 2026
Journey Medical Q2 EPS $(0.01) Beats $(0.02) Estimate, Sales $17.839M Miss $18.366M Estimate
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 93.75 percent increase over losses of $(0.16) per share from the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
